Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Peptides for Maintenance Therapy in AML
NCT07551037Phase 1Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in acute myeloid leukemia (AML) (3 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoints: Overall Survival at 1 year and Overall Remission Rate at 12 months. Started Sep 2024; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07551037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551037.